GLP-1 receptor agonists: Evolution
Timeline
The milestones from first idea to today
| Year | Milestone |
|---|---|
| 1987 | GLP-1 (7 to 37) is shown to trigger insulin release from the pancreas [1] |
| 1992 | John Eng finds exendin-4 in Gila monster venom [2] |
| 2005 | Exenatide (Byetta) is approved by the US Food and Drug Administration [2] |
| 2010 | Liraglutide, a modified human GLP-1 lasting a day, is approved in the United States for diabetes [1] |
| 2014 | Liraglutide is approved for obesity in the United States [1] |
| 2017 | Semaglutide (Ozempic) is approved for diabetes; it is approved for obesity (Wegovy) in 2021 [1] |
| 2023 | Tirzepatide, which also acts on a second gut hormone receptor (GIP), is approved for weight loss in the United States [1] |
| 2025 | WHO adds GLP-1 medicines to its Essential Medicines List and issues a global guideline on their use for obesity [3] |
as of 2026-11-11
Lineage
The technologies it came from and the ones that came from it
Works with- Inl Insulin therapy Both treat diabetes; GLP-1 drugs make the body release its own insulin when blood sugar is high [1].
- rDNA Recombinant DNA (genetic engineering) GLP-1 was found by cloning and reading the glucagon gene in the 1980s [1].
- Asa Synthetic drugs (medicinal chemistry) The drugs are made-to-order molecules designed to fit a known receptor, as in modern drug design.
as of 2026-11-11
Sources
- GLP-1-based therapy for obesity Lasker Foundation (2024 Lasker~DeBakey Clinical Medical Research Award), 2024
- Dr. John Eng to Receive Golden Goose Award The Science Coalition, 2013
- WHO issues global guideline on the use of GLP-1 medicines in treating obesity World Health Organization, 2025